"Neuroactive Steroid For The Treatment Of Mild Cognitive Impairment Associated With Parkinson'S Disease" in Patent Application Approval Process (USPTO 20240252514).

A patent application has been filed for a compound, referred to as Compound 1, that may be used to treat mild cognitive impairment (MCI) associated with Parkinson's Disease (PD). MCI is common in PD patients and is linked to decreased quality of life and impaired functioning. Compound 1 is designed to activate NMDA receptors in the central nervous system, potentially improving executive function, working memory, and learning in PD patients with MCI. The compound may be administered orally at a recommended dose of 3 mg/day. However, it is important to note that this patent application has not been assigned to a specific company or institution. [Extracted from the article]